Kazumasa Uemura (1), Shuko Yoshioka (1), Denise M. Surina-Baumgartner
(1), Tatsuo Tamagawa (1), Hisayuki Miura (2), Muneto Ueda (2), Norika Tamaya
(2), Akihisa Iguchi (2) and Nigishi Hotta (1)
(1) Third Department of Internal Medicine and (2) Department of Geriatric Medicine, Nagoya University School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan
Abstract: We investigated the effects of intracerebroventricular administration of NIK-247 (9-amino-2,3,5,6,7,8-hexahydro-1H-cyclo-penta(b)-quinoline monohydrate hydrochloride; a cholinesterase inhibitor) or MKC-231 (2-(2-oxypyrrolidin-1-yl)-N-
(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl) acetoamide; a choline uptake enhancer) on plasma glucose level in comparison with that of neostigmine administration in rats. The extents of NIK-247- and MKC-231-induced hyperglycemia were considerably less than that by neostigmine, suggesting that the potencies of the drugs to produce the peripheral hyperglycemia may be pharmacologically negligible.
Keywords: NIK-247, MKC-231, Central hyperglycemia